[1]
Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet, 2005, 365, 217-223.
[2]
Achelrod, D.; Wenzel, U.; Frey, S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am. J. Hypertens., 2015, 28, 355-361.
[3]
Calhoun, D.A.; Jones, D.; Textor, S.; Goff, D.C.; Murphy, T.P.; Toto, R.D.; White, A.; Cushman, W.C.; White, W.; Sica, D.; Ferdinand, K.; Giles, T.D.; Falkner, B.; Carey, R.M. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008, 117, 510-526.
[4]
Sarafidis, P.A.; Georgianos, P.; Bakris, G.L. Resistant hypertension its identification and epidemiology. Nat. Rev. Nephrol., 2013, 9, 51-58.
[5]
Daugherty, S.L.; Powers, J.D.; Magid, D.J.; Tavel, H.M.; Masoudi, F.A.; Margolis, K.L.; O’Connor, P.J.; Selby, J.V.; Ho, P.M. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation, 2012, 125, 1635-1642.
[6]
Williams, B. Resistant hypertension: an unmet treatment need. Lancet, 2009, 374, 1296-1298.
[7]
MacMahon, S.; Peto, R.; Cutler, J.; Collins, R.; Sorlie, P.; Neaton, J.; Abbott, R.; Godwin, J.; Dyer, A.; Stamler, J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335, 765-774.
[8]
Zheng, Y.; Yu, B.; Alexander, D.; Mosley, T.H.; Heiss, G.; Nettleton, J.A.; Boerwinkle, E. Metabolomics and incident hypertension among blacks: the atherosclerosis risk in communities study. Hypertension, 2013, 62, 398-403.
[9]
Menni, C.; Mangino, M.; Cecelja, M.; Psatha, M.; Brosnan, M.J.; Trimmer, J.; Mohney, R.P.; Chowienczyk, P.; Padmanabhan, S.; Spector, T.D.; Valdes, A.M. Metabolomic study of carotid-femoral pulse-wave velocity in women. J. Hypertens., 2015, 33, 791-796.
[10]
Kordalewska, M.; Markuszewski, M.J. Metabolomics in cardiovascular diseases. J. Pharm. Biomed. Anal., 2015, 113, 121-136.
[11]
Schanckenberg, L.K.; Beger, R.D. Metabolomic biomarkers: their role in the critical path. Drug Discov. Today. Technol., 2007, 4, 13-16.
[12]
Ciborowski, M.; Lipska, A.; Godzien, J.; Ferrarini, A.; Korsak, J.; Radziwon, P.; Tomasiak, M.; Barbas, C. Combination of LC−MS- and GC−MS-based metabolomics to study the effect of ozonated autohemotherapy on human blood. J. Proteome Res., 2012, 11, 6231-6241.
[13]
Warrack, B.M.; Hnatyshyn, S.; Ott, K.H.; Reily, M.D.; Sanders, M.; Zhang, H.; Drexler, D.M. Normalization strategies for metabonomic analysis of urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 15, 547-552.
[14]
Dunn, W.B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.; Brown, M.; Knowles, J.D.; Halsall, A.; Haselden, J.N.; Nicholls, A.W.; Wilson, I.D.; Kell, D.B.; Goodacre, R. Human Serum Metabolome (HUSERMET) Consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc., 2011, 6, 1060-1083.
[15]
Jimenez-Contreras, E.; Torres-Salinas, D.; Moreno, R.; Banos, R.; Lopez-Cozar, E. Response Surface Methodology and its application in evaluating scientific activity. Scientometrics, 2009, 79, 201-218.
[16]
Farrell, E.K.; Chen, Y.; Barazanji, M.; Jeffries, K.A.; Cameroamortegui, F.; Merkler, D.J. Primary fatty acid amide metabolism: conversion of fatty acids and an ethanolamine in N 18 TG 2 and SCP cells 1. J. Lipid Res., 2012, 53, 247-256.
[17]
Hopps, J.J.; Dunn, W.R.; Randall, M.D. Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension. Eur. J. Pharmacol., 2012, 684, 102-107.
[18]
Ciborowski, M.; Martin-Ventura, J.L.; Meilhac, O.; Michel, J.B.; Ruperez, F.J.; Tunon, J.; Egido, J.; Barbas, C. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J. Proteome Res., 2011, 10, 1374-1382.
[19]
Ren, R.; Hashimoto, T.; Mizuno, M.; Takigawa, H.; Yoshida, M.; Azuma, T.; Kanazawa, K. A lipid peroxidation product 9-oxononanoic acid induces phospholipase A2 activity and thromboxane A2 production in human blood. J. Clin. Biochem. Nutr., 2013, 5, 228-233.
[20]
Pop, D.; Sitar-Tǎut, A.; Bodisz, G.; Zdrenghea, D.; Cebanu, M.; Stanca, L. Role of secretory phospholipase A2 in women with metabolic syndrome. Indian J. Med. Res., 2013, 138, 866-872.
[21]
Ding, Y.; Wu, C.C.; Garcia, V.; Dimitrova, I.; Weidenhammer, A.; Joseph, G.; Zhang, F.; Manthati, V.L.; Falck, J.R.; Capdevila, J.H.; Schwartzman, M.L. 20-HETE induces remodeling of renal resistance arterie independent of blood pressure elevation in hypertension. Am. J. Physiol. Renal Physiol., 2013, 305, 53-63.
[22]
Claire, M.; Jacotot, B.; Robert, L. Characterization of lipids associated with macromolecules of the intercellular matrix of human aorta. Connect. Tissue Res., 1976, 4, 61-71.
[23]
Bartke, N.; Hannun, Y.A. Bioactive sphingolipids: metabolism and function. J. Lipid Res., 2009, 50, 91-96.
[24]
Wu, Q.; Zhang, H.; Dong, X.; Chen, X-F.; Zhu, Z-Y.; Hong, Z-Y.; Chai, Y-F. UPLC-Q-TOF/MS based metabolomic profiling of serum and urine of hyperlipidemic rats induced by high fat diet. J. Pharm. Anal., 2014, 4, 360-367.
[25]
Pavoine, C.; Pecker, F. Sphingomyelinases: Their regulation and roles in cardiovascular pathophysiology. Cardiovasc. Res., 2009, 82, 175-183.
[26]
Thijs, L.; Fagard, R.; Forette, F.; Nawrot, T.; Staessen, J.A. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol., 2003, 58, 403-410.
[27]
Nikolic, S.B.; Sharman, J.E.; Adams, M.J.; Edwards, L.M. Metabolomics in hypertension. J. Hypertens., 2014, 32, 1159-1169.
[28]
Mitchell, B.M.; Dorrance, A.M.; Webb, R.C. Phenylalanine improves dilation and blood pressure in GTP cyclohydrolase inhibition-induced hypertensive rats. J. Cardiovasc. Pharmacol., 2004, 43, 758-763.
[29]
Pelley, J.W.; Goljan, E.F. Rapid Review Biochemistry: With student consult, 3rd ed; Elsevier: Philadelphia, 2011.
[30]
Sakurai, H. Urate transporters in the genomic era. Curr. Opin. Nephrol. Hypertens., 2013, 22, 545-550.
[31]
Mazzali, M.; Kanbay, M.; Segal, M.S.; Shafiu, M.; Jalal, D.; Feig, D.I.; Johnson, R.J. Uric acid and hypertension: Cause or effect? Curr. Rheumatol. Rep., 2010, 12, 108-117.
[32]
Feig, D.I. The role of uric acid in the pathogenesis of hypertension in the young. J. Clin. Hypertens., 2012, 14, 346-352.
98
9